SYNTARA LIMITED (SNT)
Share Price Analysis and Chart

07/07/2026

1

Speculative Buy

$0.06

160.87%

Syntara has reported initial results in the Phase 2 trial for drug candidate SNT-4728 in isolated REM sleep behaviour disorder (iRBD).

Bell Potter notes a statistically significant reduction in neuroinflammation from baseline was evident and there were no statistically significant changes in neuroinflammation evident in other predefined regions of primary interest.

For what is a short duration trial, the broker assesses it to be "encouraging". The trial is ongoing until subjects complete six months of follow-up. Further data will be released in the second half of 2026. Speculative Buy rating and six cents target unchanged.

FORECAST
Bell Potter forecasts a full year FY26 EPS of minus -0.60 cents.
Bell Potter forecasts a full year FY27 EPS of minus -0.50 cents.

09/07/2026

1

Buy

$0.15

552.17%

Canaccord Genuity maintains a Buy rating for Syntara with a $0.15 target price following early positive clinical trial data from its SNT-4728 program.

The Phase IIa trial, assessing the dual inhibitor in isolated REM sleep behaviour disorder, demonstrated a statistically significant reduction in neuroinflammation in the putamen after 12 weeks of treatment.

The analyst notes this early safety and efficacy readout provides highly encouraging upside optionality, potentially supporting future asset-partnering discussions.

The underlying valuation remains anchored by the primary amsulostat blood cancer franchise, which targets myelofibrosis and myelodysplastic syndromes.

Pipeline momentum is expected to build into the second half of 2026 with upcoming clinical trials in high-risk hematology indications and pancreatic cancer.